[Prevention and treatment of secondary hyperparathyroidism in CKD].
نویسندگان
چکیده
2.1 Nos pacientes com DRC estágios III a V, os níveis ideais de PTH não são conhecidos. No entanto, sugerimos que os pacientes com níveis de PTH acima do limite superior de referência para o método sejam avaliados quanto à presença de hipocalcemia, hiperfosfatemia ou fração de excreção de P elevada, e deficiência de 25-hidroxivitamina D (25-vit D). Se forem detectadas alterações nesses parâmetros, estes devem ser corrigidos; sais de Ca para correção da hipocalcemia, orientação dietética e/ou uso de quelantes de P para correção da hiperfosfatemia e uso de ergocalciferol (vitamina D2) ou colecalciferol (vitamina D3) para correção da hipovitaminose D (Evidência).
منابع مشابه
Vitamin D deficiency and secondary hyperparathyroidism in pediatrics obesity
Obesity is one of the health problems in the developing and developed countries. Obesity subjects the individuals with metabolic and endocrine disorders. It is obvious that vitamin D deficiency or insufficiency may lead to secondary hyperparathyroidism. Thus, obesity increases the risk of vitamin D deficiency. Considering the high prevalence of vitamin D deficiency in children and adolescents w...
متن کاملThe role of secondary hyperparathyroidism in anemia of end stage renal disease
Introduction: secondary hyperparathyroidism is listed among the possible reasons for intensifying the anemia and resistance to erythropoietin therapy in hemodialysis patients. Although its exact mechanism is not entirely clarified, but shift of bone marrow cells to adipocytes, bone marrow fibrosis and decreased calciteriol can be the causes. However, the role of secondary hyperparathyroidism in...
متن کاملChronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey
BACKGROUND Complications of chronic kidney disease (CKD) contribute to morbidity and mortality. Consequently, treatment guidelines have been developed to facilitate early detection and treatment. However, given the high prevalence of CKD, many patients with early CKD are seen by non-nephrologists, who need to be aware of CKD complications, screening methods and treatment goals in order to initi...
متن کاملLeft Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.
Cardiovascular diseases represent the main causes of morbidity and mortality in patients with chronic kidney disease (CKD). According to a well-established classification, cardiovascular involvement in CKD can be set in the context of cardiorenal syndrome type 4. Left ventricular hypertrophy (LVH) represents a key feature to provide an accurate picture of systolic-diastolic left heart involveme...
متن کاملSagliker Syndrome in a Patient with Secondary Hyperparathyroidism and Chronic Renal Insufficiency: A Case Report
Sagliker syndrome is a rare form of renal osteodystrophy resulted from untreated secondary hyperparathyroidism. It is described by severe skeletal deformities, high level of PTH in patients with chronic renal failure, and deformed face. This paper reports a 44-year-old male patient with the mentioned characteristics. In addition to the unique clinical features, high levels of ALP and PTH hormon...
متن کاملVitamin D in kidney disease: pathophysiology and the utility of treatment.
CKD is associated with decreased vitamin D metabolites, both the storage form 25(OH)D and the active form 1,25-dihydroxyvitamin D. This contributes to hyperparathyroidism, and increased levels of PTH mobilize minerals from the skeleton and increase the risk for fractures. Treatment with vitamin D sterols efficiently reduces secondary hyperparathyroidism of CKD. Observational studies suggest sur...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
دوره 33 Suppl 1 شماره
صفحات -
تاریخ انتشار 2011